Table 3.
Cumulative incidences of neurologic and nonneurologic death at one and two years as stratified by clinical variables of interest.
| Neurologic Death | Nonneurologic Death | |||||
|---|---|---|---|---|---|---|
| 1-year CI (%) | 2-year CI (%) | P value | 1-year CI (%) | 2-year CI (%) | P value | |
| Histology | .002 | .02 | ||||
| Melanoma | 39.5 | 45.1 | 29.4 | 34.7 | ||
| Nonmelanoma | 29.5 | 34.7 | 36.8 | 49.4 | ||
| KPS | .003 | .70 | ||||
| <80% | 35.5 | 43.4 | 36.3 | 43.8 | ||
| 80%–100% | 20.6 | 31.2 | 35.3 | 48.0 | ||
| Brain metastases | <.001 | .32 | ||||
| 1–3 | 21.9 | 32.3 | 35.8 | 48.2 | ||
| 4+ | 36.6 | 49.7 | 34.6 | 40.6 | ||
| Lowest SRS dose | .006 | .02 | ||||
| ≤ 18 Gy | 30.3 | 40.1 | 30.7 | 41.6 | ||
| 19–21 Gy | 21.2 | 31.4 | 35.9 | 48.7 | ||
| > 21 Gy | 15.3 | 25.2 | 44.1 | 55.6 | ||
| Cavity-directed SRS | .24 | <.001 | ||||
| Yes | 27.2 | 36.9 | 21.6 | 34.8 | ||
| No | 22.9 | 32.9 | 40.5 | 51.4 | ||
| Extent of systemic disease | .28 | <.001 | ||||
| None | 28.3 | 38.7 | 15.9 | 28.9 | ||
| Oligometastasis | 23.2 | 32.9 | 37.3 | 51.6 | ||
| Widespread metastasis | 23.5 | 32.9 | 44.8 | 53.0 | ||
| Systemic disease status | .84 | <.001 | ||||
| Stable | 21.3 | 32.4 | 29.5 | 41.9 | ||
| Progressive | 27.8 | 34.7 | 45.9 | 57.5 | ||
| Lung histology | .06 | .44 | ||||
| Adenocarcinoma | 17.8 | 26.9 | 43.2 | 55.1 | ||
| SqCC | 32.0 | 42.7 | 38.2 | 52.8 | ||
| Targeted therapy | .04* | .60 | ||||
| Yes | 15.6 | 30.3 | 30.3 | 44.9 | ||
| No | 28.7 | 36.0 | 38.6 | 48.4 | ||
| DS-GPA | .002 | .19 | ||||
| 0–1 | 36.0 | 46.7 | 39.3 | 45.2 | ||
| 1.5–2 | 22.3 | 35.4 | 39.8 | 49.9 | ||
| 2.5–3 | 17.7 | 23.1 | 32.8 | 49.7 | ||
| >3 | 14.5 | 30.1 | 23.2 | 35.6 | ||
Abbreviations: CI, cumulative incidence; DS-GPA, diagnosis-specific graded prognostic assessment; KPS, Karnofsky performance status; SqCC, squamous cell carcinoma; SRS, stereotactic radiosurgery.
*This P value corresponds to the initial 1.5 years following SRS; over the entire 5-year post-SRS period, P = 0.25.